Holman, Alexis http://orcid.org/0000-0001-9914-3981
Kruger, Daniel J.
Lucas, Philippe
Ong, Kaye
Bergmans, Rachel S.
Boehnke, Kevin F.
Funding for this research was provided by:
Tilray Canada Ltd.
National Institute on Drug Abuse (K01DA049219)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR07080, T32-AR07080)
Article History
Received: 11 April 2022
Accepted: 31 May 2022
First Online: 13 June 2022
Declarations
:
: The survey went through ethics review and approval by Advarra, an independent Institutional Review Board service (ethics approval #Pro00050772). All participants completed electronic consent.
: Not applicable.
: Dr. Boehnke sits on a data safety and monitoring board for an ongoing clinical trial with Vireo Health (unpaid) and has received grant funding from Tryp Therapeutics unrelated to the content of this manuscript. Dr. Lucas was Vice-President, Global Patient Research and Access at Tilray, one of the study’s sponsors. Kaye Ong was employed by Tilray at the time of the study. Drs. Holman, Bergmans, and Kruger report no conflicts of interest.